Spots Global Cancer Trial Database for kinase inhibitor
Every month we try and update this database with for kinase inhibitor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer | NCT04586270 | Advanced or Met... | TAS0612 | 18 Years - | Taiho Oncology, Inc. | |
| Efficacy and Safety of Nintedanib Combined With Paclitaxel Chemotherapy for Patients With BRAF wt Metastatic Melanoma | NCT02308553 | Cutaneous Malig... | Nintedanib Nintedanib-Plac... Paclitaxel | 18 Years - | University Hospital, Essen | |
| A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body | NCT03955939 | Metastatic Brea... | LY3295668 Erbum... Endocrine thera... Midazolam | 18 Years - | Eli Lilly and Company | |
| A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body | NCT03955939 | Metastatic Brea... | LY3295668 Erbum... Endocrine thera... Midazolam | 18 Years - | Eli Lilly and Company | |
| Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies | NCT04149691 | Gastric Cancer Bladder Cancer Squamous Non-sm... Cholangiocarcin... Sarcoma Endometrial Can... Other Solid Tum... | CPL304110 | 25 Years - | Celon Pharma SA | |
| Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas | NCT04750928 | Neurofibromatos... | Abemaciclib | 12 Years - | National Institutes of Health Clinical Center (CC) | |
| Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer | NCT00075270 | Neoplasms, Brea... | Paclitaxel GW572016 (Lapat... | 18 Years - | GlaxoSmithKline | |
| A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma | NCT04106219 | Neuroblastoma | LY3295668 Erbum... Topotecan Cyclophosphamid... | 2 Years - 21 Years | Eli Lilly and Company | |
| Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies | NCT01188252 | Neoplasms | Roniciclib (BAY... | 18 Years - | Bayer | |
| A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies | NCT01004224 | Advanced Solid ... Squamous Lung C... Bladder Cancer ... Advanced Solid ... Advanced Solid ... Advanced Solid ... | BGJ398 | 18 Years - | Novartis | |
| Safety Study of AKN-028 in Patients With Acute Myelogenous Leukemia | NCT01573247 | Acute Myeloid L... | AKN-028 | 18 Years - | Akinion Pharmaceuticals AB | |
| Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer | NCT00075270 | Neoplasms, Brea... | Paclitaxel GW572016 (Lapat... | 18 Years - | GlaxoSmithKline | |
| A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer | NCT04586270 | Advanced or Met... | TAS0612 | 18 Years - | Taiho Oncology, Inc. | |
| Safety Study of AKN-028 in Patients With Acute Myelogenous Leukemia | NCT01573247 | Acute Myeloid L... | AKN-028 | 18 Years - | Akinion Pharmaceuticals AB | |
| An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leukemia | NCT00346632 | Acute Myelogeno... Acute Lymphobla... Myelodysplastic... Chronic Myeloge... | KW-2449 | 18 Years - | Kyowa Kirin Co., Ltd. | |
| Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas | NCT00727233 | Neurofibromatos... Plexiform Neuro... | Nexavar (BAY 43... Toxicity, Pharm... Pharmacodynamic... Radiographic Ev... QOL assessment,... Bony Toxicity | 3 Years - 18 Years | National Institutes of Health Clinical Center (CC) | |
| Histology-Independent Study of Palbociclib in Patients With Advanced Cancer | NCT03123744 | Cancer, Advance... | Palbociclib 125... | 18 Years - | University of California, San Diego | |
| Histology-Independent Study of Palbociclib in Patients With Advanced Cancer | NCT03123744 | Cancer, Advance... | Palbociclib 125... | 18 Years - | University of California, San Diego | |
| Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors | NCT06161558 | Neoplasms | Erlotinib Lenvatinib Axitinib | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML) | NCT01468467 | Leukemia, Myelo... | AC220 | 18 Years - | Daiichi Sankyo | |
| A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) | NCT01390337 | Leukemia, Myelo... | AC220 daunorubicin cytarabine | 18 Years - 60 Years | Daiichi Sankyo | |
| Efficacy of Sorafenib Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML | NCT00373373 | Acute Myeloid L... | Sorafenib Placebo | 61 Years - | University Hospital Muenster | |
| Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer | NCT02292173 | Hepatocellular ... Liver Cancer | Trametinib Sorafenib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS | NCT04477291 | Acute Myeloid L... Myelodysplastic... | CG-806 | 18 Years - | Aptose Biosciences Inc. | |
| Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas | NCT00727233 | Neurofibromatos... Plexiform Neuro... | Nexavar (BAY 43... Toxicity, Pharm... Pharmacodynamic... Radiographic Ev... QOL assessment,... Bony Toxicity | 3 Years - 18 Years | National Institutes of Health Clinical Center (CC) | |
| Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas | NCT04750928 | Neurofibromatos... | Abemaciclib | 12 Years - | National Institutes of Health Clinical Center (CC) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
